Shortening Anesthesia Duration does not Affect Severity of Withdrawal Syndrome in Patients Undergoing Ultra Rapid Opioid Detoxification
,
Abstract
Ultra rapid opioid detoxification (UROD) is one of the new methods of detoxification. This method of detoxification involves putting patients under general anesthesia and actively giving them opioid antagonists. The objective of this study was to evaluate effects of anesthesia duration in UROD on severity of withdrawal syndrome. Sixty addicted patients seeking UROD procedure assigned randomly to one of the 2hr, 4hr or 6hr anesthesia duration groups. Premedication and anesthesia procedure (induction and maintenance) were the same for three groups. Detoxification was done for all patients with 50 mg oral naltroxane (prior to induction) and 20 mg intravenous naloxane (8 mg/bolus and 12 mg/infusion). Blood pressure, heart rate and respiratory rate were automatically measured and recorded every 5 minutes. The severity of withdrawal syndrome was measured and recorded every one hour during anesthesia, 2hours post-anesthesia, and 12 and 24 hours following the induction of anesthesia according to the Wang Scale modified by Lomier (WSMBL). Patients aged 20-58 in three groups. Three cases experienced delirium after detoxification that lasted 24 hours in one. Severity of withdrawal syndrome in patients of groups 2, 4 and 6 hour were 8.7, 7.4 and 5.1 respectively during anesthesia and 12.3, 11.1 and 13.9 after 18 hours of anesthesia. Results of this study showed that, in standard settings, UROD is a safe method for detoxification and has low complications. The withdrawal symptoms during and after anesthesia are low. Shortening the duration of anesthesia has no affect on severity of withdrawal syndrome during and after anesthesia.
Jaffe JH, Jaffe AB. Opioid-related disorders. In: Sadock BJ, Sadock VA, editors. Kaplan and Sadock's Comprehensive Textbook of Psychiatry. 7th ed. New York: Lippincott, Williams and Wilkins; 2000. p. 1038-63.
Farrell M. Opiate withdrawal. Addiction 1994;89(11):1471-5.
Wodak A. Managing illicit drug use. A practical guide. Drugs 1994;47(3):446-57.
Simon DL. Rapid opioid detoxification using opioid antagonists: history, theory and the state of the art. J Addict Dis 1997;16(1):103-22.
Seivewright NA, Greenwood J. What is important in drug misuse treatment? Lancet 1996;347(8998):373-6.
Loimer N, Schmid RW, Presslich O, Lenz K. Continuous naloxone administration suppresses opiate withdrawal symptoms in human opiate addicts during detoxification treatment. J Psychiatr Res 1989;23(1):81-6.
Riordan CE, Kleber HD. Rapid opiate detoxification with clonidine and naloxone. Lancet 1980;1(8177):1079-80.
Vining E, Kosten TR, Kleber HD. Clinical utility of rapid clonidine-naltrexone detoxification for opioid abusers. Br J Addict 1988;83(5):567-75.
Seoane A, Carrasco G, Cabré L, Puiggrós A, Hernández E, Alvarez M, Costa J, et al. Efficacy and safety of two new methods of rapid intravenous detoxification in heroin addicts previously treated without success. Br J Psychiatry 1997;171:340-5.
Kaye AD, Gevirtz C, Bosscher HA, Duke JB, Frost EA, Richards TA, et al. Ultrarapid opiate detoxification: a review. Can J Anaesth 2003;50(7):663-71.
Bochud Tornay C, Favrat B, Monnat M, Daeppen JB, Schnyder C, Bertschy G, et al. Ultra-rapid opiate detoxification using deep sedation and prior oral buprenorphine preparation: long-term results. Drug Alcohol Depend 2003;69(3):283-8.
Fleisher LA. Risk of anesthesia. In: Miller RD, editor. Miller's Anesthesia. 5th ed. London: Churchill Livingstone; 2000. p. 795-823.
Wang RI, Wiesen RL, Lamid S, Roh BL. Rating the presence and severity of opiate dependence. Clin Pharmacol Ther 1974;16(4):653-8.
Albanese AP, Gevirtz C, Oppenheim B, Field JM, Abels I, Eustace JC. Outcome and six month follow up of patients after Ultra Rapid Opiate Detoxification (UROD). J Addict Dis 2000;19(2):11-28.
Broers B, Giner F, Dumont P, Mino A. Inpatient opiate detoxification in Geneva: follow-up at 1 and 6 months. Drug Alcohol Depend 2000;58(1-2):85-92.
Gossop M, Green L, Phillips G, Bradley B. Lapse, relapse and survival among opiate addicts after treatment. A prospective follow-up study. Br J Psychiatry 1989;154:348-53.
Rabinowitz J, Cohen H, Atias S. Outcomes of naltrexone maintenance following ultra rapid opiate detoxification versus intensive inpatient detoxification. Am J Addict 2002;11(1):52-6.
Lorenzi P, Marsili M, Boncinelli S, Fabbri LP, Fontanari P, Zorn AM, et al. Searching for a general anaesthesia protocol for rapid detoxification from opioids. Eur J Anaesthesiol 1999;16(10):719-27.
Bell JR, Young MR, Masterman SC, Morris A, Mattick RP, Bammer G. A pilot study of naltrexone-accelerated detoxification in opioid dependence. Med J Aust 1999;171(1):26-30.
Foy A, Sadler C, Taylor A. An open trial of naltrexone for opiate dependence. Drug Alcohol Rev 1998;17(2):167-74.
Cucchia AT, Monnat M, Spagnoli J, Ferrero F, Bertschy G. Ultra-rapid opiate detoxification using deep sedation with oral midazolam: short and long-term results. Drug Alcohol Depend 1998;52(3):243-50.
Rabinowitz J, Cohen H, Tarrasch R, Kotler M. Compliance to naltrexone treatment after ultra-rapid opiate detoxification: an open label naturalistic study. Drug Alcohol Depend 1997;47(2):77-86.
| Files | ||
| Issue | Vol 48, No 1 (2010) | |
| Section | Articles | |
| Keywords | ||
| Analgesic opioid substance withdrawal syndrome anesthesia | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
